Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis.

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) testing has become a promising tool to guide first-line (1L) targeted treatment for advanced non-small cell lung cancer (aNSCLC). This study aims to estimate the clinical validity (CV) and clinical utility (CU) of ctDNA-based next-generation sequencing (NGS) for oncogenic driver mutations to inform 1L treatment decisions in aNSCLC through a systematic literature review and...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Carcinoma, Non-Small-Cell Lung
• Circulating Tumor DNA
• High-Throughput Nucleotide Sequencing
• Lung Neoplasms